Form 13-F position report

GSK PLC

Reported by KAHN BROTHERS GROUP INC

GSK CUSIP 37733W204 Manager CIK 0001039565

Reported 113,552 shares, down 44,886 (28.3%) from the prior quarter.

Reported value -34.1%; share count -28.3% vs. the prior quarter.

Reduced
% of reported 13F value 0.91% This manager · Q3 2026
Shares 113,552 Quarter-end amount reported
Reported value $5,469,799 Fair value at quarter end
Consecutive quarters held 40 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 63440893
2022-03-31 62145788
2022-06-30 62297972
2022-09-30 38404190
2022-12-31 43113031
2023-03-31 45453031
2023-06-30 45029371
2023-09-30 46483403
2023-12-31 46676538
2024-03-31 53743386
2024-06-30 47788450
2024-09-30 43285078
2024-12-31 29921125
2025-03-31 31852636
2025-06-30 25339084
2025-06-30 0
2025-09-30 11257724
2025-12-31 8763251
2026-03-31 8884596
2026-06-30 8305319
2026-09-30 5469799

Quarterly position history

How this manager's reported quarter-end position changed over time.

21 quarters
Quarterly reported position history for GSK PLC held by KAHN BROTHERS GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 113,552 -44,886 (-28.3%) 0.91% $5,469,799 2026-11-16
Q2 2026 Reduced 158,438 -2,544 (-1.6%) 1.31% $8,305,319 2026-08-14
Q1 2026 Reduced 160,982 -17,714 (-9.9%) 1.58% $8,884,596 2026-05-08
Q4 2025 Reduced 178,696 -82,141 (-31.5%) 1.55% $8,763,251 2026-02-12
Q3 2025 Reduced 260,837 -399,035 (-60.5%) 2.12% $11,257,724 2025-11-12
Q2 2025 Reduced 0 -822,227 (-100.0%) 0 $0 2025-08-14
Q2 2025 New 659,872 +659,872 (0.0%) 5.09% $25,339,084 2025-08-14
Q1 2025 Reduced 822,227 -62,481 (-7.1%) 6.44% $31,852,636 2025-05-15
Q4 2024 Reduced 884,708 -174,124 (-16.4%) 6.5% $29,921,125 2025-02-14
Q3 2024 Reduced 1,058,832 -182,429 (-14.7%) 7.46% $43,285,078 2024-11-13
Q2 2024 Reduced 1,241,261 -12,383 (-1.0%) 8.03% $47,788,450 2024-08-14
Q1 2024 Reduced 1,253,644 -5,838 (-0.5%) 7.97% $53,743,386 2024-05-15
Q4 2023 Reduced 1,259,482 -22,807 (-1.8%) 7.35% $46,676,538 2024-02-13
Q3 2023 Added 1,282,289 +18,831 (1.5%) 7.25% $46,483,403 2023-11-13
Q2 2023 Reduced 1,263,458 -14,018 (-1.1%) 6.6% $45,029,371 2023-08-09
Q1 2023 Added 1,277,476 +50,570 (4.1%) 6.54% $45,453,031 2023-05-12
Q4 2022 Reduced 1,226,906 -78,033 (-6.0%) 5.68% $43,113,031 2023-02-15
Q3 2022 Reduced 1,304,939 -126,221 (-8.8%) 5.98% $38,404,190 2022-11-15
Q2 2022 Added 1,431,160 +4,496 (0.3%) 8.39% $62,297,972 2022-08-10
Q1 2022 Reduced 1,426,664 -11,905 (-0.8%) 7.89% $62,145,788 2022-05-02
Q4 2021 Added 1,438,569 +85,211 (6.3%) 8.71% $63,440,893 2022-01-25
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1101 managers reported GSK PLC for Q3 2026.

Managers reporting GSK PLC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 64,920,926 -40,715 0.13% $3,127,240,971 17 qtrs
Dodge & Cox Reduced 43,183,117 -5,014,397 1.12% $2,080,130,746 17 qtrs
Fisher Asset Management LLC Reduced 35,351,693 -371,099 0.49% $1,702,891,094 17 qtrs
PRIMECAP MANAGEMENT CO CA Added 25,192,138 +10,070 0.75% $1,213,505,291 17 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 9,650,852 -1,745,397 0.08% $464,881,541 17 qtrs
JTC Employer Solutions Trustee Ltd Reduced 8,077,477 -515,510 33.51% $389,173,000 17 qtrs
ROYAL BANK OF CANADA Added 7,652,143 +63,215 0.06% $368,604,000 17 qtrs
MORGAN STANLEY Reduced 7,584,742 -72,820 0.02% $365,357,075 17 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 6,712,097 -211,545 0.03% $323,323,000 17 qtrs
The Goldman Sachs Group Inc Reduced 6,021,779 -349,663 0.02% $290,069,075 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
113,552
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.